(Total Views: 616)
Posted On: 03/27/2021 10:32:01 PM
Post# of 155024
Re: Echo..echo #84424
With regard to the EMA approving Celltrion’s regdanvimab, Echo..echo said
EMA concluded that regdanvimab can be used in COVID-19 patients not requiring oxygen and at high risk of progressing to severe
late to the party..
Read More: https://investorshangout.com/post/newpost/605...z6qMyfJuP2
The EMA also said this per the article I linked below:
“However, the results were not robust enough to reach a firm conclusion on the medicine’s benefits at this point in time,” EMA said. “In terms of safety, most side effects reported were mild or moderate. Reactions related to the infusion (including allergic reactions) cannot be excluded and healthcare professionals should monitor patients for these reactions.”
Despite the uncertainties, EMA concluded that regdanvimab can be considered a treatment option for patients at high risk of progressing to severe Covid-19, based on a reasonable likelihood that the medicine may provide clinical benefit, and a low likelihood of harm .
https://endpts.com/ema-ongoing-study-data-of-...-patients/
The EMA's Dr. Woodcock-equivalent appears to be a person who understands that pandemics require action, not just feel-good words.
EMA concluded that regdanvimab can be used in COVID-19 patients not requiring oxygen and at high risk of progressing to severe
late to the party..
Read More: https://investorshangout.com/post/newpost/605...z6qMyfJuP2
The EMA also said this per the article I linked below:
“However, the results were not robust enough to reach a firm conclusion on the medicine’s benefits at this point in time,” EMA said. “In terms of safety, most side effects reported were mild or moderate. Reactions related to the infusion (including allergic reactions) cannot be excluded and healthcare professionals should monitor patients for these reactions.”
Despite the uncertainties, EMA concluded that regdanvimab can be considered a treatment option for patients at high risk of progressing to severe Covid-19, based on a reasonable likelihood that the medicine may provide clinical benefit, and a low likelihood of harm .
https://endpts.com/ema-ongoing-study-data-of-...-patients/
The EMA's Dr. Woodcock-equivalent appears to be a person who understands that pandemics require action, not just feel-good words.
(6)
(0)
